

Electronic Supporting Information

UOx@HMnO₂ Biozyme-Nanozyme Driven Electrochemical Platform for Specific Uric Acid Bioassays

Chenlong He^{a,1}, Huawei Liu^{a,1}, Ming Yin^a, Jing Chen^a, Wensi Huang^b, Han Zhou^a, Shengming Wu^a, Yilong Wang^{a,*}

a State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200092, P. R. China.

b School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200030, P.R. China.

*Corresponding author: yilongwang@tongji.edu.cn




Fig S1. TEM image of SiO_2 nanoparticles and $\text{SiO}_2@MnO_2$ nanoparticles.




Fig S2. (a) Size distributions and (b) Zeta potential of HMnO₂ and UOx@HMnO₂.




Fig S3. EDS spectrum of UO_x@HMnO₂ by STEM.




Fig S4. Photographs for the chromogenic reaction of TMB catalyzed by the UOx@HMnO₂.




Fig. S5. (a) Comparison of the TMB color development of UOx@HMnO₂ with equal amounts of free UOx. (b) UV absorption of UOx@HMnO₂ vs. equal amounts of free uric acid oxidase at OD650.




Fig S6. Relationship between UA concentration and current.




Fig. S7. UOx@HMnO₂-GCE was used for the long-term detection of uric acid stability, and the vertical coordinate was calculated using the CV value on day 1 as a reference.




Fig S8. Data points and standard curves for high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) tests.

Table S1. Recoveries of UA in human urine based on the UOx@HMnO₂-GCE.

Before amount (μM)	Add amount (μM)	Found amount (μM)	Recovery (%)
32.80	10	41.09	96.00
34.22	20	66.32	103.27
33.24	40	74.87	102.22